*British Columbia Centre for Excellence in HIV/AIDS*

**SAFETY DATA SHEET**

1. **PRODUCT AND COMPANY IDENTIFICATION**

**Lyophilized powder for proficiency testing (PT) and/or external quality assessment (EQA) for therapeutic drug level monitoring (TDM&UDL) after reconstitution. See separate SDS for reconstituted samples.**

|  |  |  |
| --- | --- | --- |
| **Product name** | **Product Number** | **Supplier** |
| MassCheck® Anti-HIV Drugs Plasma Control | 0261 Bi-Level, 0262 Level I, 0263 Level II | **Chromsystems Instruments & Chemicals GmbH**  Am Haag 12; 82166 Gräfelfing Germany  Phone: +49 89 18930-0 Fax: +49 89 18930-299  E-mail: [mailbox@chromsystems.com](mailto:mailbox@chromsystems.com)  Homepage: [www.chromsystems.com](http://www.chromsystems.com) |
| Antivirals Survey | Panel 850 | **INSTAND e.V.**  Postfach 250211, D – 40093 Duesseldorf  Tel: +49 211 1592 13 0  E-mail: [instand@instand-ev.de](mailto:instand@instand-ev.de)  Homepage: [www.instand-ev.de](http://www.instand-ev.de) |
| Antiretroviral Drugs Panel - Holland Samples | Antiretroviral Drugs | **SKML**  Mercator 1, Toernooiveld 214, 6525 EC Nijmegen  Tel: +31 24 361 66 37, Fax: +31 24 356 06 86  E-mail: [office@skml.nl](mailto:office@skml.nl) |
| ASQUALAB  Antiviral-Antiretroviral | AR15  AR16 | **ASQUALAB**  Quality assurance of medical biology laboratories  Bâtiment Leriche – 96, rue Didot - 75014-PARIS  Tel. +33 1 45 40 35 75  E-mail: asqualab@wanadoo.fr  Homepage: [www.asqualab.com](http://www.asqualab.com) |

**Recommended Usage:** This product is for research and development purposes.

1. **HAZARDS IDENTIFICATION**

**Emergency Overview**

This preparation contains human serum or plasma. All controls of human origin should be considered as potentially infectious and treated with appropriate care.

1. **COMPOSITION/INFORMATION ON INGREDIENTS**

This product is derived from human blood and/or blood products, spiked with antiretrovirals at various concentration levels. It has been lyophilized by the supplier.

1. **FIRST AID MEASURES**

If accidental contact with material occurs laboratory staff must follow local first aid procedures that are normally applied following exposure to an equivalent clinical specimen. Medical advice should be sought following exposure to the material.

Eyes: In case of eye contact, flush eyes with plenty of water for at least 15 minutes. Separate eyelids with fingers to assure complete flushing. Consult a physician immediately.

Skin: In case of contact with skin, wash with a copious amount of water for at least 15 minutes. Remove any contaminated clothing and shoes and wash before re-wearing.

Ingestion: In case of ingestion, wash mouth out with water provided the person is conscious. Consult a physician immediately.

1. **FIREFIGHTING MEASURES**

Not applicable.

1. **ACCIDENTAL RELEASE MEASURES**

Personal precautions: Avoid breathing vapours, mist or gas. Wear appropriate protective equipment and clothing during handling.

Methods for cleaning up: Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. If samples are spilled, decontaminate by using a suitable surface disinfectant. After-wards contain and collect carefully using suitable absorbent materials. Clean up surface with water after disinfection.

Environmental precautions: Material must not end up in sewage, waters or soil.

1. **HANDLING AND STORAGE**

Handling: Avoid skin and eye contact. Wear personal protective equipment. Handle and open with care.

Storage: Store samples according to the information on the sample tube or in the instruction sheet with individual distributions.

1. **EXPOSURE CONTROLS/PERSONAL PROTECTION**

**Respiratory protection:** Respiratory protection not required.

**Eye protection:** Masks, in combination with goggles or glasses with solid shields, should be worn whenever eye contamination can be reasonably anticipated. Working within a BSC can be an alternative.

**Skin protection:** Gloves must be worn whenever handling this product. Disposable gloves must be replaced as soon as possible whenever contamination occurs, and must not be washed or decontaminated for re-use.

**Body protection**: Protective Clothing: Appropriate protective clothing such as gowns, aprons, lab coats, and clinic jackets should be work in occupational exposure situations. Surgical caps or hoods should be worn whenever gross contamination can be reasonably anticipated

.

1. **PHYSICAL AND CHEMICAL PROPERTIES**

**Physical State:** Powder (Lyophilized)

**Appearance:** White toOff-white

**Odor:** NA

**Refer to the Product Datasheet for physical and chemical properties.**

1. **STABILITY AND REACTIVITY**

**Chemical stability:** Stable under recommended storage conditions.

**Possibility of hazardous reactions:** No information available

1. **TOXICOLOGICAL INFORMATION**

To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated.

1. **ECOLOGICAL INFORMATION**

**Toxicity:** No information available

**Persistence and degradability:**  No information available

**Bioaccumulative potential:** No information available

**Mobility in soil:**  No information available

**PBT and vPvB assessment:** No information available

**Other adverse effects:** No information available

1. **DISPOSAL CONSIDERATIONS**

Disposal of this product should be made in accordance with existing procedures/protocols for disposal of infectious waste. Observe all Federal, State and Local environmental regulations.

1. **TRANSPORT INFORMATION**

**DOT (US):** Not dangerous goods

**IMDG:** Not dangerous goods

**IATA:** Not dangerous goods

1. **REGULATORY INFORMATION**

**WHMIS Classification:** Not WHMIS controlled.

1. **OTHER INFORMATION**

**Further information**

The above information is believed to be correct but does not purport to be all inclusive and shall be used only as a guide. The information in this document is based on the present state of our knowledge and is applicable to the product with regard to appropriate safety precautions. It does not represent any guarantee of the properties of the product.

**Document Revision History**

Date Created: 29-April-2019

Document Author: Birgit Watson, BC-CfE Laboratory Safety Officer

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Version # | Date | Section Changed | Change(s) Made | Updated By | |
|  | | | | |  | |
| 1 | 29-Apr-2019 | All | New Document |  | |
| 2 | 24-Sept-2025 | Product and Company Identification  Revision history | Asqualab Controls added  Added revision history | Nadia Moran  BC-CfE Laboratory Safety Officer | |